Windtree Therapeutics Announces Issuance of New Dual Mechanism SERCA2a Activator Patent
Compounds that activate SERCA2a may lead to novel therapies for heart failure WARRINGTON, Pa. , April 17, 2023 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT), a biotechnology company focused on advancing late-stage interventions for cardiovascular
Article Date
April 17, 2023
This article is featured on another website.
Go to article
September 6, 2023
MD Anderson and Panacea launch Manaolana Oncology to develop antibody-based therapies for cancer
The University of Texas MD Anderson Cancer Center and Panacea Venture today announced the launch of Manaolana Oncology Inc., a new company created to develop and advance antibody-based therapies against novel cancer antigens.
September 6, 2023
MD Anderson and Panacea launch Manaolana Oncology to develop antibody-based therapies for cancer
The University of Texas MD Anderson Cancer Center and Panacea Venture today announced the launch of Manaolana Oncology Inc., a new company created to develop and advance antibody-based therapies against novel cancer antigens.